(Q42670642)

4 November 2017

title

Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae (English)

1 reference

4 November 2017

main subject

Streptococcus pneumoniae

1 reference

C T Ong

1

1 reference

4 November 2017

P K Dandekar

2

1 reference

4 November 2017

C Sutherland

3

1 reference

4 November 2017

C H Nightingale

4

1 reference

4 November 2017

D P Nicolau

5

1 reference

4 November 2017

publication date

13 October 2005

1 reference

4 November 2017

1 reference

4 November 2017

volume

51

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

339-346

1 reference

Pulmonary disposition of antimicrobial agents: methodological considerations

4 November 2017

cites work

1 reference

Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens

21 January 2018

1 reference

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin

21 January 2018

1 reference

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

21 January 2018

1 reference

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000088958

1 reference

4 November 2017

1 reference